Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Nutr Biochem. 2021 Aug 15;99:108842. doi: 10.1016/j.jnutbio.2021.108842

Figure 4. Effects of curcumin on TGFβR2 localization and signaling in cells expressing wildtype TGFβR2 (MDA-SA) vs. a truncated TGFβR2 lacking the cytoplasmic domain (MDA-SA-TGFβR2Δcyt).

Figure 4.

A) Membrane-associated (vs soluble) TGFβR2, Smad2, and MAPK proteins in MDA-SA cells treated with curcumin (30 μM, 4h pre-treatment) and/or TGFβ (1h). B) TGFβR2 in sodium/potassium ATPase-enriched plasma membrane (vs. intracellular) actin-enriched fractions from curcumin-treated (30 μM, 4h) MDA-SA cells. C) Early (4h) or D) late (16h) effects of curcumin (30 uM) on TGFβR2, MAPK and/or Smad signaling in cells pre-treated for 1h with a lipid raft disrupter (nystatin, 50 μg/mL [39]) and/or inhibitor of clathrin-dependent endocytosis (Pitstop 2, 20 μM [60]). Note: A single blot is shown in D with intervening unrelated data omitted. E) Effect of absent TGFβR2 cytoplasmic domain on Smad and MAPK signaling proteins or F) PTHrP secretion (n=4/group) in MDA-SA vs. MDA-TGFβR2Δcyt cells pre-treated with curcumin (30 μM) prior to TGFβ stimulation. * p < 0.05, **** p < 0.0001 vs control or as specified. N = nystatin, P = Pitstop 2, B = nystatin and Pitstop 2